Category: biotechnology & health
BNL Reference Number: BSA 08-25
Patent Status: U.S. Patent Number 8,030,526 was issued on October 4, 2011
Trimethylamine N-oxide will react with [11C]methyliodide to form [11C]formaldehyde. This new reaction provides a method to access [11C]formaldehyde without the need for special reagents or conditions. It is anticipated that the widespread availability of [11C]formaldehyde will increase the number of compounds that can be labeled with carbon-11 for use in positron emission tomography (PET), a non-invasive way to image molecular interactions in the human body.
Formaldehyde represents a unique reagent for various synthetic routes to drug compounds. Its use as a precursor reagent in the synthesis of 11C labeled positron emission tomography (PET) tracers has been limited due to lack of simple, easily adapted methods of making it from cyclotron-derived 11C- CO2. This method makes 11C - Formaldehyde a readily available synthetic reagent.
The present invention provides a simple, efficient method for production of radiolabeled formaldehyde. Methods for production of [11C]-formaldehyde (11CH2O) for use in positron emission tomography (PET) are provided as are methods for synthesis of 14C, 13C, deuterium and tritium labeled formaldehyde.
The oxidation state of[11C]-formaldehyde (11CH2O) provides a way to insert carbon-11 into compounds for use in PET imaging through new routes. Lack of a simple synthetic route for 11CH2O production has heretofore stymied its routine use. The present invention makes use of commercially available reagents and mild conditions to convert [11C]-methyl iodide (11CH3I) to [11C]-formaldehyde (11CH211C isotopic dilution. The reaction can be readily automated for incorporation into commercial PET tracer synthesis modules.
A wide variety of synthetic routes are possible using 11CH2O, including reductive methylations, ring-closure reactions, electrophilic aromatic substitutions, Mannich-type condensations, and cyclization reactions. Thus, readily available 11CH2O enables the development and use of many new radioliglands.
For more information about this technology, contact Christine Brakel, (631) 344-7134.
Tags: PET, pharmaceutical